Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction.

Luis Ortega-PazHelena CristóbalJosé Tomás Ortiz-PerezPablo García de FrutosGuiomar MendietaElena SandovalJuan José RodriguezEmilio OrtegaAna García-ÁlvarezSalvatore BrugalettaManel SabatéAna Paula Dantas

Published in: ESC heart failure (2022)

SGLT2i, LCZ696, and spironolactone modulate the function of isolated myocardial fibroblasts from HFrEF patients through the activation of different signalling pathways. The combination of SGLT2i + LCZ696 shows an additive effect on migration, while spironolactone modifies the signalling pathways activated by SGLT2i and its beneficial effects of biomarkers of heart failure.

Keyphrases

heart failure
left ventricular
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
patient reported outcomes